Halozyme Therapeutics
HALO
#2390
Rank
S$8.39 B
Marketcap
$65.96
Share price
7.22%
Change (1 day)
21.85%
Change (1 year)

Revenue for Halozyme Therapeutics (HALO)

Revenue in 2024 (TTM): S$1.25 Billion

According to Halozyme Therapeutics's latest financial reports the company's current revenue (TTM ) is S$1.27 Billion. In 2023 the company made a revenue of S$1.09 Billion an increase over the revenue in the year 2022 that were of S$0.88 Billion. The revenue is the total amount of income that a company generates by the sale of goods or services. Unlike with the earnings no expenses are subtracted.

Revenue history for Halozyme Therapeutics from 2002 to 2024

Annual revenue

Year Revenue Change
2024 (TTM) S$1.25 B14.45%
2023 S$1.09 B23.76%
2022 S$0.88 B47.66%
2021 S$0.59 B69.29%
2020 S$0.35 B33.98%
2019 S$0.26 B27.36%
2018 S$0.20 B-51.01%
2017 S$0.42 B99.46%
2016 S$0.21 B11.13%
2015 S$0.19 B91.92%
2014 S$99.54 M43.37%
2013 S$69.43 M34.14%
2012 S$51.75 M-28.74%
2011 S$72.63 M313.89%
2010 S$17.54 M-8.56%
2009 S$19.19 M53.13%
2008 S$12.53 M129.24%
2007 S$5.46 M263.19%
2006 S$1.5 M
2003 S$0.03 M-80.2%
2002 S$0.15 M

Revenue for similar companies or competitors

Company Revenue Revenue differencediff. Country
S$0.33 B-73.78%๐Ÿ‡บ๐Ÿ‡ธ USA
S$55.01 B 4,213.41%๐Ÿ‡บ๐Ÿ‡ธ USA
S$20.18 B 1,483.04%๐Ÿ‡บ๐Ÿ‡ธ USA
S$74.90 B 5,773.41%๐Ÿ‡บ๐Ÿ‡ธ USA
S$72.03 B 5,548.06%๐Ÿ‡ซ๐Ÿ‡ท France
S$118.05 B 9,156.93%๐Ÿ‡บ๐Ÿ‡ธ USA